Formulation Development
Interius BioTherapeutics Doses First Patient With In Vivo Chimeric Antigen Receptor Gene Therapy for B-Cell Malignancies
Interius BioTherapeutics recently announced the first study participant has been dosed in INVISE, its first-in-human Phase 1 clinical trial of INT2104, a first-in-class gene therapy…
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor
Nimbus Therapeutics, LLC recently announced it presented preclinical data on its new development candidate, NTX-452, a novel Werner syndrome helicase (WRN) inhibitor, at the 36th…
Lonza Extends Collaboration With Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Lonza recently announced a long-term extension of its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. The extended agreement will expand…
PolTREG Launches Phase 2 Cell Therapy Trial in Children With Presymptomatic Diabetes
PolTREG S.A. has launched a placebo-controlled Phase 2 clinical trial with PTG-007 Treg cell therapy in presymptomatic type-1 diabetes (T1D) patients, after receiving approval from…
Rentschler Biopharma Announces Largest Single Investment at its Headquarters in Germany
Rentschler Biopharma SE recently announced the construction of a new state-of-the-art buffer media station at its company headquarters in Laupheim. The new facility aims to…
Rhythm Pharmaceuticals & Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. and Axovia Therapeutics Ltd. recently announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome (BBS). “We believe there…
UPM Biomedicals Launches FibGel, World’s First Injectable Nanocellulose Hydrogel for Medical Devices
UPM Biomedicals recently announced the launch of FibGel, a natural injectable hydrogel for permanent implantable medical devices. FibGel is a nanofibrillar cellulose hydrogel made from…
GRI Bio Raises $13.9 Million in Gross Proceeds Since the Beginning of 2024
GRI Bio, Inc. recently announced it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 762,236 shares…
BirchBioMed Receives Health Canada Green Light to Start the Last Stage of its Groundbreaking Clinical Program to Minimize Scarring From Burns
BirchBioMed recently announced the authorization from Health Canada to conduct its Phase 2/3 randomized clinical trial of a naturally based compound, FS2, at multiple centers…
Novadip Reports Promising Interim Results From First-in-Human Proof-of-Concept Trial of New Game Changer in Bone Field
Novadip Biosciences recently announced positive interim results from its first-in-human clinical trial, NVDX3-CLN01, assessing the safety and efficacy of NVDX3 to heal distal radius fractures…
Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION Platform
Avacta Group plc recently announced the addition of two novel preclinical oncology assets, AVA6103 and AVA7100, to its pipeline of pre|CISION-enabled drug conjugates. Avacta is…
Immutep Announces First-in-Human Phase 1 Study of IMP761 Progresses to Dose Escalation Portion of Trial
Immutep Limited recently announced the first part (Part A, single dose) of the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761 has been fully recruited…
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Immune Regulator for Treatment of Acute Respiratory Distress Syndrome
BioAegis Therapeutics recently announced the first patient has been enrolled in the company’s Phase 2 study of rhu-pGSN for the treatment of Acute Respiratory Distress…
Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications
Biognosys recently announced its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany. The company…
WEBINAR - Lipid Nanoparticle (LNP) Characterization: Leveraging HPLC-CAD for Lipid Quantification Assay
Whether you’re involved in research, development, or quality control, this webinar will equip you with the knowledge and tools you need to enhance your analytical processes and ensure success in your LNP projects.
mRNA Licensing Agreements Surge 800% in Value as Confidence Grows Beyond Vaccines
Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800% increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success…
Cullinan Therapeutics Receives IND Clearance for CLN-978 Administered Subcutaneously in Patients With Moderate-to-Severe Systemic Lupus Erythematosus
Cullinan Therapeutics, Inc. recently announced the US FDA cleared the Company’s Investigational New Drug (IND) Application for CLN-978 and its global Phase 1 clinical trial…
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients With Neuropathic Corneal Pain
OKYO Pharma Limited recently announced that screening and recruitment of patients has started for a Phase 2 trial of OK-101 to treat NCP. The Phase…
IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IGNX001 in Peanut Allergy
IgGenix, Inc. recently announced the first patient dosed in its ACCELERATE Peanut Phase 1 clinical trial. The trial aims to evaluate IGNX001, a novel therapeutic…
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Ltd. recently announced positive proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD). WVE-006 is…
